Search 

We are a clinical stage biopharma company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders

Founded in March 2017, IASO BIO is engaged in the development and industrialization of tumor cell immunotherapy drugs. Launched in Nanjing Biotech and Pharmaceutical Valley, the company has a total of 7,000㎡ of R&D platform and GMP pilot platform, and almost 10,000㎡ of commercial space in Nanjing. It also has a 1,750㎡ R&D platform in Zhangjiang Hi-tech Park ( Shanghai) and a global R&D center of approximately 57,000 square meters under construction in Shanghai Pilot Free Trade Zone. The company currently employs 350 staff.

A clinical stage bio pharmaceutical company focus on immunotherapy of tumor and autoimmune diseases.

Private Equity investment platform of ICBC.

ICBC Asia investment is a wholly-owned holding equity investment platform of industrial and commercial bank of China (ICBC). Managing over 44 billion yuan unlist equity investment. Direct investment over 172 projects, indirect investment in over 2400 companies.

Idience Co. Ltd. (“Idience’) is a NRDO (No Research & Development Only) company focusing on oncology treatment. The company was established in 2019 by Ildong Holdings Group, a holding company of leading pharmaceutical and healthcare companies in South Korea.

Our first asset, IDX-1197 is a PARP inhibitor for various solid cancers including breast cancer and ovarian cancer. Its ongoing Phase 1a multi-center study showed a promising result. In October 2019, Idience received approval for its initial Investigational New Drug (IND) application from the Korea Ministry of Food and Drug Safety to start a Phase 1b/2a clinical trial for IDX-1197.

Idience is looking for corporate partners to discover and develop oncology therapeutics. We are open to all license-in and license-out partners.

Founded in June 2019, with a focus on high-performance medical devices, the Innovation Center of High-Performance Medical Device is devoted to boosting collaboration as well as in-depth integration and innovation of the "Clinical Practice - Scientific Research - Industry - Market"
ecosystem to build high-quality industrial clusters of medical devices by aggregating and utilizing the innovation resources of the Guangdong-Hong Kong-Macao Greater Bay Area and also international resources based on solid clinical practice and industrial basis of Guangdong Province.

IHM-GBA is short for Innovation center of High-performance Medical device in Greater Bay Area. It's based in Guangzhou of Guangdong province in China. We focus on investment, partnership, and collaboration in global disruptive technology in medical device. We aim at helping global startups to enter into and develop the Chinese market. We are in comprehensive discussion with companies in terms of investment, partnership, licensing, and others.

Illumina is a provider of Next Generation Sequencing technology

Illumina Ventures is an independently managed firm focused on early-stage companies that are pioneering new applications of genomics and enabling precision medicine. Illumina Ventures invest in life science tools, clinical diagnostics, therapeutics, and other opportunities to improve human health.

Immetas discovers and develops novel therapeutics that modulate the innate immune system to treat age-related cancers and inflammatory diseases. The company’s approach is based on emerging evidence that chronic low-grade inflammation is a fundamental process governing aging and age-related diseases, and anchored in clinical evidence to mitigate development risk. Immetas was founded by J. Gene Wang, MD, PhD, a veteran in discovery and translational drug development in immunology/ inflammation and oncology, and David Sinclair, PhD, Professor of Genetics at Harvard Medical School and a leader in the molecular mechanisms of aging. The lead program in the company’s growing pipeline is focused on engineering bispecific antibodies to modulate inflammation in the tumor microenvironment and overcome resistance to the conventional immune checkpoint therapies. Learn more at www.immetas.com